How Pulmonary Embolism Is Treated

When a person is found to have had an acute pulmonary embolus (a blood clot that lodges in the pulmonary artery) the appropriate treatment depends on whether their cardiovascular status is stable or unstable.

Caucasian doctor talking to Senior patient in hospital
JGI/Tom Grill / Getty Images

For Relatively Stable People

Although PE can be a life-threatening illness, most patients do well with medical treatment and can live a normal life afterwards. For those with more severe forms of PE there are more aggressive therapies that have substantially reduced the risk of dying and long-term disability. Stable people with pulmonary embolism are conscious and alert, and their blood pressure is not dangerously low.

For these people, treatment with anticoagulant drugs (blood thinners) is usually begun right away.

Treatment guidelines released by the American Society of Hematology (ASH) in 2020 conditionally recommend that people in relatively stable condition with an uncomplicated pulmonary embolism may be treated effectively at home instead of in the hospital.

First 10 Days

For the first 10 days after the pulmonary embolus has occurred, treatment consists of one of the following anticoagulant drugs:

  • Low molecular weight (LMW) heparin, such as Lovenox or Fragmin, which are purified derivatives of heparin that can be given by skin injection instead of intravenously
  • Arixtra (fondaparinux), another subcutaneously administered heparin-like drug
  • Unfractionated heparin, “old-fashioned” heparin that is given intravenously
  • Xarelto (rivaroxiban) or Eliquis (apixaban), two of the “new oral anticoagulant drugs” (NOAC) that are an oral substitute for Coumadin (warfarin)

All of these drugs work by inhibiting clotting factors, proteins in the blood that promote thrombosis.

Today, most doctors will use either Xarelto or Eliquis during the first 10 days of therapy in people who are able to take oral medication. Otherwise, LMW heparin is most commonly used.

10 Days to 3 Months

After the initial 10 days of therapy, treatment is selected for longer-term therapy.

In most cases, long-term therapy is continued for at least three months and in some cases for up to a year.

This longer-term treatment almost always consists of one of the NOAC drugs. For this phase of treatment (that is, after the first 10 days), the NOAC drugs Pradaxa (dabigatran) and Savaysa (edoxaban) are also approved for use, in addition to Xarelto and Eliquis. In addition, Coumadin remains an option for this long-term treatment.

Indefinite Treatment

In some people, long-term anticoagulation therapy should be used indefinitely after a pulmonary embolism, possibly for the rest of their lives. Generally, these are people fall into one of two categories:

  • People who have had a pulmonary embolus or a severe deep vein thrombosis without any identifiable provoking cause
  • People in whom the provoking cause is likely to be chronic, such as active cancer, or a genetic predisposition to abnormal blood clotting

If Anticoagulant Drugs Cannot Be Used

In some people, anticoagulant drugs are not an option. This may be because the risk of excess bleeding is too high or they may have had recurrent pulmonary embolism despite adequate anticoagulation therapy. In these people, a vena cava filter should be used.

A vena cava filter is a device that is placed in the inferior vena cava (the major vein that collects blood from the lower extremities and delivers it to the heart) by a catheterization procedure.

These vena cava filters “trap” blood clots that have broken loose and prevent them from reaching the pulmonary circulation.

Vena cava filters can be quite effective, but they are not preferred to anticoagulant drugs because of the risks involved with their use. These include thrombosis at the site of the filter (which may lead to recurrent pulmonary embolism), bleeding, migration of the filter to the heart, and erosion of the filter.

Many modern vena cava filters can be retrieved from the body by a second catheterization procedure if they are no longer needed.

For Unstable People

For some people, a pulmonary embolus can cause a cardiovascular catastrophe. In these people, the embolus is large enough to cause a major obstruction of blood flow to the lungs, which leads to cardiovascular collapse. These people usually display extreme tachycardia (rapid heart rate) and low blood pressure, pale sweaty skin, and altered consciousness.

In these cases, simple anticoagulation therapy—which primarily works by stabilizing blood clots and preventing further clotting—is not enough. Instead, something must be done to break up the embolus that has already occurred, and restore the pulmonary circulation.

Thrombolytic Therapy (“Clot Busters”)

With thrombolytic therapy, intravenous drugs are administered that “lyse” (break up) clots that have already formed. By breaking up a large blood clot (or clots) in the pulmonary artery, they can restore a person’s circulation.

The drugs used in thrombolytic therapy (also known as fibrinolytic drugs because they work by disrupting fibrin in clots) carry a substantial risk of bleeding complications, so they are used only when a pulmonary embolus is immediately life-threatening.

The thrombolytic agents most often used for severe pulmonary embolism are Activase (alteplase), Streptase (streptokinase), and Kinlytic (urokinase).

The 2020 updated ASH treatment guidelines recommend thrombolytic therapy followed by anticoagulation instead of anticoagulation alone in patients with pulmonary embolism and an unstable cardiovascular condition.


If thrombolytic therapy cannot be used because the risk of excessive bleeding is deemed to be too high, an attempt can be made at embolectomy. An embolectomy procedure attempts to mechanically break up a large clot in the pulmonary artery, either by surgery or by a catheter procedure.

The choice between catheter-based or surgical embolectomy usually depends on the availability of doctors who have experience with either of these procedures, but in general, catheter-based embolectomy is preferred because it can usually be done more quickly.

An embolectomy procedure of either type always carries major risks—including rupture of the pulmonary artery, with cardiac tamponade and life-threatening hemoptysis (bleeding into the airways).

So, embolectomy is usually only performed in people judged to be extremely unstable and who have a very high risk of death without immediate effective treatment.

Frequently Asked Questions

  • Can an embolism be surgically removed?

    Yes, but surgical embolectomy, the removal or breakup of a large blood clot via surgery, is only used in cases where the embolism is life-threatening or other treatments aren't successful. Doctors will assess your overall health and risk of heart failure before considering a surgical embolectomy.

  • What are clot busters?

    These are drugs used for thrombolytic therapy to dissolve blood clots. The medication may be used to to treat severe pulmonary embolisms and are followed by anticoagulation medication.

  • Can you die from a pulmonary embolism?

    Untreated, your risk of dying from a pulmonary embolism is 30%. However, it drops to 8% if you’re diagnosed and treated, so seeing a doctor as soon as you notice symptoms is extremely important.

7 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41(1):32-67. doi:10.1007/s11239-015-1317-0

  2. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020 Oct 13;4(19):4693-4738. doi: 10.1182/bloodadvances.2020001830.

  3. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S. doi:10.1378/chest.11-2301

  4. Aymard T, Kadner A, Widmer A, et al. Massive pulmonary embolism: Surgical embolectomy versus thrombolytic therapy--Should surgical indications be revisited? Eur J Cardiothorac Surg 2013; 43:90. doi:10.1093/ejcts/ezs123

  5. Kalra R, Bajaj NS, Arora P, Arora G, et al. Surgical embolectomy for acute pulmonary embolism: Systematic review and comprehensive meta-analyses. Ann Thorac Surg. 2017 Mar;103(3):982-990. doi:10.1016/j.athoracsur.2016.11.016

  6. Society for Vascular Surgery. Thrombolytic therapy

  7. Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013;18(2):129-138.

By Richard N. Fogoros, MD
Richard N. Fogoros, MD, is a retired professor of medicine and board-certified in internal medicine, clinical cardiology, and clinical electrophysiology.